John Willy Haukeland

  • Consultant MD, PhD
 

Publications 2016

Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O (2016)
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study
PLoS One, 11 (11), e0166451
DOI 10.1371/journal.pone.0166451, PubMed 27846264

Publications 2015

Otterdal K, Haukeland JW, Yndestad A, Dahl TB, Holm S, Segers FM, Gladhaug IP, Konopski Z, Damås JK, Halvorsen B, Aukrust P (2015)
Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation
Clin Transl Gastroenterol, 6, e95
DOI 10.1038/ctg.2015.23, PubMed 26133108

Publications 2013

von Volkmann HL, Havre RF, Løberg EM, Haaland T, Immervoll H, Haukeland JW, Hausken T, Gilja OH (2013)
Quantitative measurement of ultrasound attenuation and Hepato-Renal Index in Non-Alcoholic Fatty Liver Disease
Med Ultrason, 15 (1), 16-22
DOI 10.11152/mu.2013.2066.151.hlv1qmu2, PubMed 23486619

Publications 2012

Lannerstedt H, Konopski Z, Sandvik L, Haaland T, Løberg EM, Haukeland JW (2012)
Combining transient elastography with FIB4 enhances sensitivity in detecting advanced fibrosis of the liver
Scand J Gastroenterol, 48 (1), 93-100
DOI 10.3109/00365521.2012.746389, PubMed 23205894

Publications 2011

Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI (2011)
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies
Eur J Endocrinol, 166 (3), 503-10
DOI 10.1530/EJE-11-0864, PubMed 22170794

Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P (2011)
Activin A in nonalcoholic fatty liver disease
Vitam Horm, 85, 323-42
DOI 10.1016/B978-0-12-385961-7.00015-9, PubMed 21353887

Publications 2010

Dahl TB, Haukeland JW, Yndestad A, Ranheim T, Gladhaug IP, Damås JK, Haaland T, Løberg EM, Arntsen B, Birkeland K, Bjøro K, Ulven SM, Konopski Z, Nebb HI, Aukrust P, Halvorsen B (2010)
Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease
J Clin Endocrinol Metab, 95 (6), 3039-47
DOI 10.1210/jc.2009-2148, PubMed 20392873

Publications 2009

Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K (2009)
Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial
Scand J Gastroenterol, 44 (7), 853-60
DOI 10.1080/00365520902845268, PubMed 19811343

Yndestad A, Haukeland JW, Dahl TB, Bjøro K, Gladhaug IP, Berge C, Damås JK, Haaland T, Løberg EM, Linnestad P, Birkeland K, Konopski Z, Halvorsen B, Berge RK, Aukrust P (2009)
A complex role of activin A in non-alcoholic fatty liver disease
Am J Gastroenterol, 104 (9), 2196-205
DOI 10.1038/ajg.2009.318, PubMed 19532130

Aasheim ET, Frigstad SO, Søvik TT, Birkeland KI, Haukeland JW (2009)
Hyperinsulinemic hypoglycemia and liver cirrhosis presenting after duodenal switch: a case report
Surg Obes Relat Dis, 6 (4), 441-3
DOI 10.1016/j.soard.2009.11.007, PubMed 20096646

Publications 2008

Haukeland JW, Schreiner LT, Lorgen I, Frigstad SO, Bang C, Raknerud N, Konopski Z (2008)
ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis
Scand J Gastroenterol, 43 (10), 1241-8
DOI 10.1080/00365520802158614, PubMed 18609128

Publications 2007

Haukeland JW, Bjøro K (2007)
[When the brain fails in liver failure]
Tidsskr Nor Laegeforen, 127 (11), 1490
PubMed 17551548

Haukeland JW, Lorgen I, Schreiner LT, Frigstad SO, Brandsaeter B, Bjøro K, Bang C, Raknerud N, Konopski Z (2007)
Incidence rates and causes of cirrhosis in a Norwegian population
Scand J Gastroenterol, 42 (12), 1501-8
DOI 10.1080/00365520701478014, PubMed 17852839

Publications 2006

Haukeland JW, Aukrust P (2006)
Inflammatory interactions between nonalcoholic fatty liver disease and the metabolic syndrome
J. Hepatol., 45 (6), 881-882

Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P (2006)
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
J Hepatol, 44 (6), 1167-74
DOI 10.1016/j.jhep.2006.02.011, PubMed 16618517

Publications 2005

Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, Birkeland K, Bjøro K (2005)
Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease
Scand J Gastroenterol, 40 (12), 1469-77
DOI 10.1080/00365520500264953, PubMed 16293559

Publications 2001

Haukeland JW, Konopski Z, Bell H, Raknerud N (2001)
[Non-alcoholic steatohepatitis]
Tidsskr Nor Laegeforen, 121 (20), 2377-80
PubMed 11603045

Publications 2000

Haukeland JW, Jahnsen J, Raknerud N (2000)
[Carbamazepine-induced hepatitis]
Tidsskr Nor Laegeforen, 120 (24), 2875-7
PubMed 11143408

Publications 1999

Haukeland JW, Bøhmer T (1999)
[Severe hypophosphatemia--an overlooked condition?]
Tidsskr Nor Laegeforen, 119 (4), 538-40
PubMed 10081379

Publications 1996

Haukeland JW (1996)
[Seroxat combined with Meravean--increased risk of hemorrhage?]
Tidsskr Nor Laegeforen, 116 (29), 3528-9
PubMed 9019863

Page visits: 419